Oral Toxicity of Indium in Rats: Single and 28‐Day Repeated Administration Studies

Oral Toxicity of Indium in Rats: Single and 28‐Day Repeated Administration Studies: Keiko Asakura, et al. Department of Preventive Medicine and Public Health, Keio University School of Medicine—Indium is widely used in the electronics industry to make semiconductors, liquid‐crystal panels, and plasma display panels, and its production is increasing. However, it is necessary to handle it more cautiously than before, because the pulmonary toxicity of inhaled indium has been identified. The present study aimed to characterize the potential toxic effects of indium through oral administration and observation for fourteen days following a single dose of 0 or 2,000 mg/kg (acute oral toxicity study), and repeated oral administration for 28 days at dose levels of 0, 40, 200, or 1,000 mg/kg daily (28‐day repeated oral dose toxicity study) to male and female Crj:CD (SD) IGS rats (SPF). No deaths and no abnormalities in clinical signs, body weights, and necropsy findings were observed for any of the animals in the acute oral toxicity study. Furthermore, no changes related to indium were also observed in the dose groups up to 1,000 mg/kg of the 28‐day repeated oral dose toxicity study. From the results described above, the lethal dose 50% (LD50) of indium is greater than 2,000 mg/kg under these study conditions, and the no‐observed‐adverse‐effect‐level (NOAEL) is considered to be 1,000 mg/kg for males and females under these conditions.

[1]  K. Sekizawa,et al.  Interstitial Pneumonia Developed in a Worker Dealing with Particles Containing Indium‐tin Oxide , 2003, Journal of occupational health.

[2]  C. Weinberg,et al.  Lead Induced Nephrotoxicity: Kidney Calcium as an Indicator of Tubular Injury , 1989 .

[3]  M. Stoltenberg,et al.  Decreased serum testosterone levels in rats exposed intraperitoneally to bismuth subnitrate , 2002, Journal of applied toxicology : JAT.

[4]  D. E. Carter,et al.  Tissue distribution and elimination of indium in male Fischer 344 rats following oral and intratracheal administration of indium phosphide. , 1994, Journal of toxicology and environmental health.

[5]  P. Malfertheiner European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Maasticht 2-2000 Consensus Report , 2002 .

[6]  Y. Nishiwaki,et al.  Exposure to hardly soluble indium compounds in ITO production and recycling plants is a new risk for interstitial lung damage , 2007, Occupational and Environmental Medicine.

[7]  D. Dixon,et al.  Pulmonary toxicity to intratracheally administered indium trichloride in Fischer 344 rats. , 1994, Fundamental and Applied Toxicology.

[8]  Pornkiat Churnjitapirom,et al.  Effects of heat treatments and Sn, Ga and In additives on mechanical properties of 35Ag-30Pd-20Au-15Cu alloy. , 2004, Dental materials journal.

[9]  A. Tanaka,et al.  Pulmonary Squamous Cyst Induced by Exposure to Indium Arsenide in Hamsters , 2003, Journal of occupational health.

[10]  T. Chonan,et al.  Interstitial pulmonary disorders in indium-processing workers , 2006, European Respiratory Journal.

[11]  M. Stoltenberg,et al.  Leydig cell death in rats exposed to bismuth subnitrate , 2003, Journal of applied toxicology : JAT.

[12]  S. Peddada,et al.  The role of oxidative stress in indium phosphide-induced lung carcinogenesis in rats. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  K. Kishi,et al.  Pulmonary fibrosis in an individual occupationally exposed to inhaled indium-tin oxide , 2005, European Respiratory Journal.

[14]  Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-90-7) in F344/N rats and B6C3F1 mice (inhalation studies). , 2001, National Toxicology Program technical report series.

[15]  M. Stoltenberg,et al.  Gastrointestinal and systemic uptake of bismuth in mice after oral exposure. , 2003, Pharmacology & toxicology.

[16]  R. Quirce,et al.  In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma. , 2007, Clinical nuclear medicine.

[17]  S. Kneifel,et al.  [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor–Targeted Therapy for Insulinoma , 2007, Clinical Cancer Research.